Guggenheim analyst Michael Schmidt maintained a Buy rating on Exelixis (EXEL – Research Report) on March 26 and set a price target of $42.00. The company’s shares closed last Friday at $36.70.

Learn how to use Excel Copilot to clean data, create formulas, and visualize insights effortlessly. Perfect for professionals ...

Investors in Exelixis Inc (Symbol: EXEL) saw new options become available this week, for the November 21st expiration. One of the key inputs that goes into the price an option buyer is willing to ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The company’s shares closed yesterday at $37.01.

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024 ...

Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of unresectable, locally advanced or metastatic pancreatic ...

Sign up for the Marketplace newsletter to get the day’s biggest business stories, our economic analysis, and explainers to help you live smarter, straight to your ...

The best logo maker is an essential design tool for anyone looking to differentiate their brand online. My round-up here offers apps ideal for designers and non-designers who need to help their ...

The best free logo maker is a great choice for those who need to create logos for their businesses without paying for subscriptions or licenses. I'll cut to the chase: for a free logo designer ...

Reigning spreadsheet champ Michael Jarman thinks he's still smarter than AI, but are his days numbered? Here's what it takes ...